logo
Culp Completes Sale of Canada Manufacturing Facility

Culp Completes Sale of Canada Manufacturing Facility

Business Wire12-05-2025

HIGH POINT, N.C.--(BUSINESS WIRE)--Culp, Inc. (NYSE: CULP), a leading provider of fabrics for bedding and upholstery fabrics for residential and commercial furniture, today announced the completion of the sale of its mattress fabric manufacturing facility in Quebec, Canada. The transaction occurred in the first week of the Company's new fiscal year and marks the completion of the restructuring plan announced approximately one year ago. The purchase price for the facility was CA$8.6 million (USD$6.2 million), with CA$2.0 million (USD$1.4 million) received at closing and the balance to be paid with interest over the course of six to 12 months. The Company currently expects to realize approximately $3.0 to $3.5 million in cash proceeds net of all taxes and commissions, which it intends to use to reduce outstanding debt and enhance financial flexibility.
Iv Culp, President and Chief Executive Officer of Culp, Inc., commented, 'I'd like to thank our team for their efficiency in executing on our restructuring plan. Our ability to reshape the cost structure of our mattress fabric business and complete the final step of selling our facility in Canada within a year is a testament to their focus and dedication. We were pleased to monetize the facility in what ultimately proved to be a softer local industrial market than originally anticipated that was made more challenging by some rezoning and utility service issues impacting the property. Exiting the facility also allows us to avoid monthly carrying costs in the six figures for insurance, maintenance and the like going forward, and the cash proceeds from the sale further strengthen our balance sheet and liquidity as we enter our new fiscal year.'
Culp continued, 'I'd also like to thank all of our former associates and the community in Quebec for their contributions to the long run of success we enjoyed there. Consolidating our Canada operations into our U.S. platform was a difficult decision, but we never hesitate to make changes when in the best interests of our customers and shareholders. Our new streamlined operating model, along with an expanded U.S. manufacturing capacity and nearshore and offshore options in Haiti/Dominican Republic, Vietnam, Turkey and China, offers customers a uniquely flexible and cost-effective supply chain to bring their products to market in the current trade environment.'
About the Company
Culp, Inc. is one of the largest marketers of fabrics for bedding and upholstery fabrics for residential and commercial furniture in North America. The company markets a variety of fabrics to its global customer base of leading bedding and furniture companies, including fabrics produced at Culp's manufacturing facilities and fabrics sourced through other suppliers. Culp has manufacturing and sourcing capabilities located in the United States, China, Haiti, Turkey, and Vietnam.
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934). Such statements are inherently subject to risks and uncertainties that may cause actual events and results to differ materially from such statements. Forward-looking statements are statements that include projections, expectations, or beliefs about future events or results or otherwise are not statements of historical fact. Such statements are often but not always characterized by qualifying words such as 'expect,' 'believe,' 'will,' 'may,' 'should,' 'could,' 'potential,' 'continue,' 'target,' 'predict', 'seek,' 'anticipate,' 'estimate,' 'intend,' 'plan,' 'project,' and their derivatives, and include but are not limited to statements about expectations, projections, or trends for our future operations, strategic initiatives and plans, restructuring actions, production levels, new product launches, sales, profit margins, profitability, operating (loss) income, capital expenditures, working capital levels, cost savings (including, without limitation, anticipated cost savings from restructuring actions), income taxes, SG&A or other expenses, pre-tax (loss) income, earnings, cash flow, and other performance or liquidity measures, as well as any statements regarding dividends, share repurchases, liquidity, use of cash and cash requirements, ending cash balances and cash positions, borrowing capacity, investments, potential acquisitions, cash and non-cash restructuring and restructuring-related charges, expenses, and/or credits, net proceeds from restructuring related asset dispositions, future economic or industry trends, public health epidemics, or future developments. There can be no assurance that we will realize these expectations or meet our guidance, or that these beliefs will prove correct. Factors that could influence the matters discussed in such statements, as well as other factors that could affect our future operations or financial results and the matters discussed in forward-looking statements, is included in Item 1A 'Risk Factors' in our most recent Form 10-K and Form 10-Q reports filed with the Securities and Exchange Commission.
Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements included in this release are made only as of the date of this report. Unless required by United States federal securities laws, we neither intend nor assume any obligation to update these forward-looking statements for any reason after the date of this release to conform these statements to actual results or to changes in our expectations. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. Additional risks and uncertainties that we do not presently know about or that we currently consider to be immaterial may also affect our business operations or financial results.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union

Business Wire

timean hour ago

  • Business Wire

CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).

Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025
Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025

Business Wire

timean hour ago

  • Business Wire

Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025

OSLO, Norway--(BUSINESS WIRE)-- Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed in over half a billion devices, has shipped its AI Virtual Smart Sensor Platform™ on four smartphone models in May 2025. Xiaomi announced one smartphone: the Xiaomi Civi 5 Pro. vivo shipped three smartphones: the vivo IQOO Z10 Turbo Series and vivo Y300 GT Smartphones. For 2025 year-to-date, Elliptic Labs has launched on a total of 24 smartphone models. 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on four smartphone models in May 2025, bringing our total to 24 smartphone model launches year-to-date.' - Laila Danielsen, CEO of Elliptic Labs Share 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on four smartphone models in May 2025, bringing our total to 24 smartphone model launches year-to-date,' said Laila Danielsen, CEO of Elliptic Labs. AI Virtual Proximity Sensor INNER BEAUTY Elliptic Labs' AI Virtual Proximity Sensor detects when a user holds their phone up to their ear during a call, allowing the smartphone to turn off its display and disable its screen's touch functionality. This keeps the user's ear or cheek from triggering unwanted actions during the call, such as hanging up or dialing numbers. Turning off the screen also helps conserve battery life. Proximity detection is a core capability that is used in all smartphones, but Elliptic Labs' AI Virtual Proximity Sensor is a unique, software-only solution that delivers robust proximity detection without the need for a dedicated hardware sensor. By replacing hardware sensors with software sensors, the AI Virtual Proximity Sensor reduces device cost and eliminates sourcing risk. INNER BEAUTY is a registered trademark of Elliptic Labs. AI Virtual Smart Sensor, AI Virtual Proximity Sensor, and AI Virtual Smart Sensor Platform are trademarks of Elliptic Labs. All other trademarks or service markets are the responsibility of their respective organizations. About Elliptic Labs Elliptic Labs' AI Virtual Smart Sensor Platform™ brings contextual intelligence to devices, enhancing user experiences. Our technology uses proprietary deep neural networks to create AI-powered Virtual Smart Sensors that improve personalization, privacy, and productivity. Currently deployed in over 500 million devices, our platform works across all devices, operating systems, platforms, and applications. By utilizing system-level telemetry data to cloud-based Large Language Models (LLMs), the AI Virtual Smart Sensor Platform delivers the unrivaled capability to utilize output data from every available data source. This approach allows devices to better understand and respond to their environment, making technology more intuitive and user-friendly. At Elliptic Labs, we're not just adapting to the future of technology – we're actively shaping it. Our goal is to continue pushing the boundaries of contextual intelligence, creating more intuitive and powerful experiences for users worldwide. Elliptic Labs is headquartered in Norway with presence in the USA, China, South-Korea, Taiwan, and Japan. The company is listed on the Oslo Stock Exchange. Its technology and IP are developed in Norway and are solely owned by the company.

Cosmo First commissions new BOPP Film Line at Aurangabad plant
Cosmo First commissions new BOPP Film Line at Aurangabad plant

Business Upturn

timean hour ago

  • Business Upturn

Cosmo First commissions new BOPP Film Line at Aurangabad plant

By Aman Shukla Published on June 2, 2025, 10:12 IST Cosmo First Ltd, a global supplier of films for packaging, lamination, labelling, and synthetic paper, has successfully commissioned a new BOPP (Biaxially Oriented Polypropylene) film line at its manufacturing facility in Aurangabad, Maharashtra. The new BOPP line involves a capital expenditure of over ₹400 crore and adds an annual production capacity of 81,200 metric tonnes (MT). With this addition, Cosmo First's total annual BOPP capacity rises by approximately 40%, reaching 2,77,000 MT. This development is part of the company's strategic initiative to scale up production and meet the growing demand for speciality packaging films. Cosmo First has recorded a 10% CAGR in speciality film sales over the past six years. The expanded capacity is expected to support the launch of several new speciality products in the coming quarters. The company stated that the new line features advanced manufacturing technology, aimed at enhancing efficiency and broadening its product offerings in the speciality films and packaging segments. Pankaj Poddar, Group CEO, Cosmo First, stated, 'We expect the line to get filled fast due to current favourable gap in demand and supply in the domestic industry. Further, the new BOPP film line shall be eligible for state govt incentives beside being the most cost-efficient line in India. The Company's focus will be on taking full leverage of the new investments including BOPP line and grow specialty film sales.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store